CA
OCUL icon

Cetera Advisors’s Ocular Therapeutix OCUL Stock Holding History

Cetera Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$6.58M Buy
723,490
+676,963
+1,455% +$4.8M 0.05% 365
2023
Q4 		$208K Sell
46,527
-4,935
-10% -$14.6K ﹤0.01% 1621
2023
Q3 		$162K Sell
51,462
-1,370
-3% -$5.61K ﹤0.01% 1565
2023
Q2 		$273K Sell
52,832
-2,073
-4% -$12.3K ﹤0.01% 1355
2023
Q1 		$289K Buy
54,905
+1,958
+4% +$9.3K ﹤0.01% 1303
2022
Q4 		$149K Buy
52,947
+1,285
+2% +$4.25K ﹤0.01% 1475
2022
Q3 		$214K Buy
51,662
+2,078
+4% +$10.5K 0.01% 1106
2022
Q2 		$199K Buy
49,584
+2,040
+4% +$7.71K ﹤0.01% 1246
2022
Q1 		$235K Buy
47,544
+4,391
+10% +$24.3K ﹤0.01% 1231
2021
Q4 		$301K Sell
43,153
-43,763
-50% -$340K 0.01% 1117
2021
Q3 		$869K Buy
+86,916
New +$976K 0.02% 663

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Cetera Advisors's OCUL Position: Q1 2024 in Review

Cetera Advisors increased its Ocular Therapeutix (OCUL) stake by 1,455% in Q1 2024, buying an estimated $4.8M and bringing the position to 723,490 shares worth $6.58M. The position accounts for 0.05% of the portfolio, ranked #365.

Cetera Advisors first reported a position in OCUL in Q3 2021 and has held it in 11 quarters since. 148 funds tracked by Wall St. Rank hold OCUL as of Q1 2024.

  • Cetera Advisors held 723,490 shares of Ocular Therapeutix worth $6.58M as of Q1 2024.
  • Cetera Advisors bought 676,963 Ocular Therapeutix shares in Q1 2024, an estimated $4.8M.
  • Ocular Therapeutix made up 0.05% of Cetera Advisors's portfolio in Q1 2024, its #365 holding.
  • Cetera Advisors first reported a position in Ocular Therapeutix in Q3 2021 and has held it in 11 quarters since.
  • 148 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.